ISRG Intuitive Surgical Inc

Intuitive Surgical designs, manufactures, and markets the da Vinci robotic surgical system and related instruments used in minimally invasive surgery worldwide. Sector: Healthcare.

Intuitive Surgical Inc (ISRG) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

From a returns-on-capital standpoint, ROIC is 19.68%, WACC is 13.87%, and the economic spread is 5.81%. On balance, the company clears its capital cost hurdle modestly — value creation is present but not emphatic. Supporting metrics show ROE at 16.64% and ROA at 11.98%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that is value-creative but with less room for execution slippage.

The current pricing of the company reads trailing P/E of 57.37, forward P/E of 45.10, PEG of 2.80. A meaningful compression from trailing to forward P/E implies analysts are projecting earnings growth that could re-rate the company favorably if delivered. The PEG reading here is above the range most value-oriented investors would find comfortable — the valuation requires a high degree of confidence in forward earnings delivery. The aggregate current ratio of 4.87 points to strong liquidity for the company. In aggregate, the valuation reads as fair to moderately stretched — leaving the investment case dependent on earnings execution rather than multiple expansion.

On profitability at each income statement layer, gross margin sits at 66.00%, operating margin at 29.27%, and free cash flow margin at 24.75%. Gross margins are well above average, signaling strong production-level economics across the company. At this operating margin level, the the company demonstrate competent cost management and reasonable earnings durability. Free cash flow margins are strong, reflecting capital-efficient businesses that largely self-fund their growth. Across gross, operating, and free cash flow layers, profitability quality appears consistently strong for this company.

Looking at growth and market-implied direction, TTM revenue growth of 18.76% indicating top-line growth that is constructive without being speculative. At the same time, the estimated 12-month price change of 33.03%, where target-based upside appears notably strong in the current setup. It's worth distinguishing between what businesses are actually delivering and what the market is being asked to believe about the next 12 months. Maintaining alignment between reported results and forward estimates is particularly important in periods where macro uncertainty is elevated. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The composite of ROIC spread, valuation, revenue momentum, and analyst expectations delivers a rare alignment of quality and growth that justifies elevated conviction.

This summary is based on publicly available quantitative data and is not intended as investment advice. Carefully consider your personal financial circumstances before making any decisions.